Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT06220864 Recruiting - Clinical trials for Advanced Solid Tumor

SNV1521 in Participants With Advanced Solid Tumors

Start date: February 23, 2024
Phase: Phase 1
Study type: Interventional

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one.

NCT ID: NCT06220318 Recruiting - Solid Tumor Clinical Trials

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Start date: July 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

NCT ID: NCT06219083 Recruiting - Cancer Clinical Trials

Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy

Start date: November 12, 2020
Phase:
Study type: Observational [Patient Registry]

The study investigates the impact of nutritional status on the clinical outcomes of cancer patients in Shaanxi Province undergoing chemoradiotherapy. It focuses on understanding how diet and nutrition affect the effectiveness and side effects of cancer treatments.

NCT ID: NCT06218628 Recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Start date: April 5, 2024
Phase: Phase 1
Study type: Interventional

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.

NCT ID: NCT06214143 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

NCT ID: NCT06211647 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-XT117 injection in patients with FAP-positive advanced solid tumors. Dose escalation will be conducted to determine the Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D), and to assess dosimetry characteristics.

NCT ID: NCT06210815 Recruiting - Solid Tumor Clinical Trials

A Study of HLX42 in Advanced/Metastatic Solid Tumors

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

NCT ID: NCT06209385 Recruiting - Solid Tumor Clinical Trials

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

Start date: August 11, 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants with Advanced Solid Tumors

NCT ID: NCT06208410 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.

NCT ID: NCT06208371 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM

Start date: January 15, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases. We aim to answer the following question: Can localized interventions, including surgery and/or ablation and/or stereotactic body radiotherapy (SBRT), enhance the 5-year survival rate compared to palliative chemotherapy alone in patients with ≥10 colorectal liver metastases (CRLM)? Participants in this study, who have achieved disease control through chemotherapy, will undergo either localized interventions (surgery and/or ablation and/or SBRT) or receive palliative chemotherapy alone. Researchers will compare the survival outcomes between these groups to determine the potential benefits of localized interventions for patients with ≥10 CRLM.